Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), Point-of-Care Tests), Age Group (Adult Screening, Newborn Screening, Years 1 to 25), Sector - Global Forecast 2024-2030

Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), Point-of-Care Tests), Age Group (Adult Screening, Newborn Screening, Years 1 to 25), Sector - Global Forecast 2024-2030

The Sickle Cell Anemia Testing & Screening Market size was estimated at USD 943.95 million in 2023 and expected to reach USD 1,070.69 million in 2024, at a CAGR 13.51% to reach USD 2,293.22 million by 2030.

Sickle cell anemia, known as sickle cell disease (SCD), is a genetic disorder that affects hemoglobin, the molecule in RBCs that delivers oxygen to cells throughout the body. People with sickle cell anemia have hemoglobin S, which can warp red blood cells into a sickle, or crescent, shape. These sickled cells can cause chronic pain, serious infections, and other complications because they do not flow through blood vessels easily and can block blood flow to parts of the body. Increasing prevalence of sickle cell anemia across the globe driving the adoption of testing & screening solutions. In addition, expanding healthcare infrastructure in emerging economies supports greater access to and adoption of testing and screening services. However, the high cost of genetic testing and limited reimbursement policies can impede market growth, particularly in low-income countries. Furthermore, innovations in molecular diagnostics and high-throughput screening methods are streamlining the testing process, increasing its accuracy, and reducing turnaround times.

Regional Insights

In the American region, there is a high consumer need for accurate and early diagnosis, as well as routine screening. This is reflected in established newborn screening programs and initiatives such as the Sickle Cell Disease Newborn Screening Program by the CDC. Customer purchasing behavior in these regions is influenced by healthcare insurance policies and coverage for genetic testing. The awareness and screening for sickle cell anemia vary across EU countries. Countries in the European region, where the disease is more prevalent, have more robust screening programs. The European Hematology Association is one organization actively engaging in research. The EU consumer purchasing behavior for SCA testing is motivated by healthcare regulations and the availability of national health services. The sickle cell anemia testing and screening market in Africa is significant due to the high prevalence of the disease. There is a growing demand for affordable and available testing options for SCA. Sickle cell anemia is slightly prevalent in East Asian countries such as Japan and China, corresponding to India, where it remains a public health concern. In India, SCA screening is incorporated into broader health initiatives, particularly in tribal regions. Consumer needs in the Asia Pacific region vary, but there is increasing awareness about genetic diseases and the benefits of early testing.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Sickle Cell Anemia Testing & Screening Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Prevalence of Sickle Cell Disease Worldwide
    • Ongoing Government Initiatives to Support the Diagnosis
    • Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
    • Market Restraints
      • Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
      • Market Opportunities
        • Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
        • Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
        • Market Challenges
          • Clinical Heterogeneity and Complications Associated with SCD
          • Lack of Resources and Skilled Clinical Laboratory Workforce Shortages
          • Market Segmentation Analysis
            • Technology: Ongoing advancements hemoglobin electrophoresis for initial screening particularly in newborns
            • Sector: Corporate labs are at the forefront of innovation and technology to provide comprehensive services
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Sickle Cell Anemia Testing & Screening Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Sickle Cell Anemia Testing & Screening Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • USD 3 million awarded to study repurposing of blood pressure drug for SCD
              
              Indiana University School of Medicine's research initiative received a significant boost through a USD 3-million grant from the U.S. Department of Defense, targeting the repurposing of a blood pressure medication, propranolol, to treat cardiac complications associated with Sickle Cell Disease (SCD). The research aims to address SCD's intricate cardiovascular consequences by examining propranolol's efficacy in preclinical SCD models, a move that could expedite its therapeutic application due to its established consumption history.
              
              Mylab introduces indigenous Point-of-care, Rapid Sickle Cell Anemia Test
              
              Mylab Discovery Solutions has introduced the PathoCatch Sickle Cell Rapid Test. This strip-based, point-of-care test, sanctioned by the CDSCO, offers swift and precise diagnosis directly at the patient's location, potentially revolutionizing SCA management. Early and accurate detection is made possible without complex laboratory equipment, streamlining the process traditionally marked by lengthy and intricate lab analysis.
              
              Lord’s Mark Industries, IIT-Bombay partner to advance sickle cell testing in India
              
              The Indian Institute of Technology Bombay (IIT-B) has joined forces with Lord's Mark Industries to revolutionize sickle cell disease testing and screening in India. By introducing an AI-powered, patent-pending point-of-sale (POS) device, IIT-B responds to the dire need for rapid and reliable diagnostic methods. This groundbreaking tool offers unprecedented accuracy and user convenience, enabling fast differentiation among healthy, sickle cell trait, and sickle cell anemia blood samples directly at the primary care point.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Sickle Cell Anemia Testing & Screening Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Sickle Cell Anemia Testing & Screening Market, highlighting leading vendors and their innovative profiles. These include Agios Pharmaceuticals, Inc., Anamol Laboratories Pvt. Ltd., Atlas Medical GmbH, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., Biomedomics Inc., Bluebird bio, Inc., Calibre Scientific, Inc., CRISPR Therapeutics AG, Edvotek Inc., Hemex Health, HiMedia Laboratories, Laboratory Corporation of America Holdings, Maternova Inc., PerkinElmer, Inc., Pfizer Inc., PicnicHealth, Quest Diagnostics Incorporated, Silver Lake Research Corporation, Streck, Inc., Thermo Fisher Scientific Inc., Ulta Lab Tests, LLC, and Vertex Pharmaceuticals Incorporated.
            
            Market Segmentation & Coverage
            
            This research report categorizes the Sickle Cell Anemia Testing & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Technology
              • Hemoglobin Electrophoresis
                • Isoelectric focusing
                • High-performance Liquid Chromatography (HPLC)
                • Point-of-Care Tests
                  • Lateral Flow Immunoassay
                  • Paper Based Rapid Diagnostics
                  • Age Group
                    • Adult Screening
                    • Newborn Screening
                    • Years 1 to 25
                    • Sector
                      • Corporate Labs
                      • Government Labs
                      • Private Labs
                      • Public-Private-Partnerships
                      • Region
                        • Americas
                          • Argentina
                          • Brazil
                          • Canada
                          • Mexico
                          • United States
                            • California
                            • Florida
                            • Illinois
                            • New York
                            • Ohio
                            • Pennsylvania
                            • Texas
                            • Asia-Pacific
                              • Australia
                              • China
                              • India
                              • Indonesia
                              • Japan
                              • Malaysia
                              • Philippines
                              • Singapore
                              • South Korea
                              • Taiwan
                              • Thailand
                              • Vietnam
                              • Europe, Middle East & Africa
                                • Denmark
                                • Egypt
                                • Finland
                                • France
                                • Germany
                                • Israel
                                • Italy
                                • Netherlands
                                • Nigeria
                                • Norway
                                • Poland
                                • Qatar
                                • Russia
                                • Saudi Arabia
                                • South Africa
                                • Spain
                                • Sweden
                                • Switzerland
                                • Turkey
                                • United Arab Emirates
                                • United Kingdom
                                
                                
                                Please Note: PDF & Excel + Online Access - 1 Year